secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K/A
Filed at:   2023-11-22T23:59:59+00:00
Accession:  0001104659-23-120777
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals dismisses KPMG as auditor, appoints Salberg & Company
-------------------------------------------------------------------------

- Dismissed KPMG effective Nov 15, 2023; no disagreements in past two fiscal years.
- KPMG's reports for FY2021 and FY2022 included a going concern qualification.
- Material weakness in segregation of duties identified for 2021 through Q3 2022; remediated as of Dec 31, 2022.
- Engaged Salberg & Company as new independent auditor for FY2023, effective Nov 17, 2023.
- No prior consultations with Salberg on any accounting or auditing matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923120777/0001104659-23-120777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923120777/tm2331382d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-120777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer